The global antibody market size is estimated to be worth around 266.83 billion in 2024. The total market value of the antibodies sector is anticipated to increase at a CAGR of 8.1% from 2024 to 2033. Furthermore, it is anticipated that the market for antibodies will reach USD 581.42 billion by 2034. The total market growth of the antibodies sector represented in absolute dollars is USD 315 billion.
| Report Attribute | Details |
|---|---|
| Antibody Market Size (2024) | USD 266.83 billion |
| Market Anticipated Forecast Value (2034) | USD 581.42 billion |
| Market Projected Growth Rate (2024 to 2034) | 8.1% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global antibody market was valued at USD 131.47 billion in 2019. The market overview of antibody drugs progressed at an annual rate of 12.5% between 2019 and 2023. The overall market value was about USD 236.86 billion by 2023.
| Attributes | Details |
|---|---|
| Antibody Market Value (2019) | USD 131.47 billion |
| Market Revenue (2023) | USD 236.86 billion |
| Market Historical Growth Rate (CAGR 2019 to 2023) | 12.5% CAGR |
Research and Development Activities Impact Antibodies Sales Outlook
A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies is driving growth opportunities for diagnostic specialty antibody suppliers.
In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.
Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries.
In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.
Increasing Production of Bio-similar Antibodies is Driving Demand
Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported USD 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated USD 659 million in 2020.
USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.
One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to further drive the market in the upcoming years.
The table below mentions the countries that are expected to witness higher growth opportunities in this market.
| Regional Market Comparison | CAGR (2024 to 2034) |
|---|---|
| United States | 9.6% |
| Germany | 9.4% |
| United Kingdom | 10.1% |
| India | 9.5% |
| China | 6.5% |
The United States therapeutic antibodies market is poised to advance at a rate of 10.1% per year till 2034.
Consumption of antibody products in the United Kingdom is projected to rise at a rate of 10.1% during the forecast years.
The antibodies industry in China is projected to thrive at a CAGR of 5.8% through the projected years.
Sales of antibodies in Germany are anticipated to increase at a rate of 9.4% from 2024 to 2034.
Demand for antibodies in India is expected to rise at a rate of 9.5% per year between 2024 and 2034.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Based on product type, the monoclonal antibodies market segment is estimated to account for 95% of the market share in 2024.
| Attributes | Details |
|---|---|
| Top Product Type or Segment | Monoclonal Antibodies |
| Total Market Share in 2024 | 95% |
Based on disease indication, the use of antibodies for treating cancer is expected to account for 57% of the total sales in 2024.
| Attributes | Details |
|---|---|
| Top Disease Indication Type or Segment | Cancer |
| Total Market Share in 2024 | 57% |
Leading market players are working towards developing new antibodies to remain competitive in the present market. They are also researching to create long-acting antibody drugs to reduce healthcare costs and attract chronic patients.
In order to gain a competitive edge in the antibody testing market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.
Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.
Recent Developments in the Global Antibody Market
On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around USD 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities through expansion into autoantibody-driven disease.
Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately USD 6 billion in possible milestone payments through this agreement.
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | USD 266.83 billion |
| Projected Market Size (2034) | USD 581.42 billion |
| Anticipated Growth Rate (2024 to 2034) | 8.1% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD million or billion for Value and Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; Middle East & Africa (MEA); East Asia; South Asia and Oceania |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa |
| Key Segments Covered | By Product Type, By Disease Indication, By End Use Verticals, and By Region |
| Key Companies Profiled | Novartis AG; F. Hoffmann-La Roche AG; Johnson & Johnson; Takeda Pharmaceutical Company Limited; Amgen Inc. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global antibody market is estimated to be around USD 266.83 billion in 2024.
The global antibody market is to grow at 8.1% during the forecast period.
The global antibody market is predicted to be valued at USD 581.42 billion by 2034.
The global antibody market was valued at USD 131.47 billion in 2019.
The United Kingdom to witness 10.1% CAGR in sales of antibodies through 2034.
| Estimated Market Size (2025E) | USD 3.4 billion |
|---|---|
| Projected Market Value (2035F) | USD 4.8 billion |
| Value-based CAGR (2025 to 2035) | 3.6% |
| Market Size (2023) | USD 235.0 billion |
|---|---|
| Market Size (2033) | USD 824.0 billion |
| Market CAGR (2023 to 2033) | 13.4% |
Explore Life Science & Biotechnology Insights
View Reports
Antibody Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
